Fresenius Kabi SwissBioSim

Fresenius Kabi SwissBioSim is the specialized biosimilars research and development division of Fresenius Kabi, a global healthcare company. Established in 2017 following the acquisition of Merck KGaA's biosimilars business, the company is headquartered in Eysins, Switzerland. It focuses on developing high-quality, affordable biologic therapies primarily in the therapeutic areas of immunology and oncology. The company's portfolio includes several approved biosimilars, such as Idacio (adalimumab), Stimufend (pegfilgrastim), Tyenne (tocilizumab), and the recently approved denosumab biosimilars Conexxence and Bomyntra. Fresenius Kabi SwissBioSim leverages its state-of-the-art R&D center and the global manufacturing and commercial infrastructure of its parent company to expand patient access to critical biopharmaceuticals worldwide.